← Back to search
BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
BOSTON, MA, 02215
UnclaimedClaim this profile (free)
Prime contracting experience
2 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services Food and Drug Administration | THE PRIMARY OBJECTIVE OF THIS REQUIREMENT IS TO MAKE THE RICH CLINICAL INFORMATION ENCODED BY BILLIONS OF REAL-WORLD LABORATORY TEST RESULTS AVAILABLE TO EVERYONE, FREE OF CHARGE, IN AN EFFORTLESS YET HIPAA COMPLIANT MANNER, TO ADVANCE REGULATORY SCI | — | $2,000,000 | Sep 19, 2025 | Jan 19, 2024 – Jan 18, 2025 |
| Prime | Department of Health and Human Services Office of the Assistant Secretary for Administration | ACCESS, EXCHANGE, AND USE OF SOCIAL DETERMINANTS OF HEALTH DATA IN CLINICAL NOTES | — | $328,306 | Sep 9, 2025 | Sep 30, 2020 – Sep 29, 2023 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
16 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | STATEMENT OF WORK – YEAR 7 (BASE) – BAROUCH LAB
DURING THE PRECEDING YEARS OF THE AWARD, WE FOCUSED ON DEVELOPING AN INNOVATIVE AND PHYSIOLOGICALLY RELEVANT MOUSE CHALLENGE MODEL THAT UNDERGOES REPEATED ULTRA-LOW DOSE MTB EXPOSURES TO ASSESS THE PROTECTIVE EFFICACY OF TB VACCINES. IN YEAR 6, WE SUCCESSFULLY ESTABLISHED AND VALIDATED A HIGHLY REPRODUCIBLE MURINE REPEATED ULTRA-LOW DOSE CHALLENGE MODEL WITH REDUCED STRINGENCY. USING THIS MODEL, WE TESTED THE PROTECTIVE EFFICACY OF BCGS AND ΔLPRG VACCINES. UNDER THE REPEATED ULTRA-LOW DOSE EXPOSURE MODEL, ΔLPRG IMMUNIZATION CONFERRED ~65% PROTECTION AGAINST ACQUISITION OF INFECTION, COMPARED WITH ~45% PROTECTION OBSERVED WITH THE SINGLE ULTRA-LOW DOSE CHALLENGE, REPRESENTING A SIGNIFICANT IMPROVEMENT IN VACCINE-INDUCED PROTECTION. WE ALSO EXPANDED OUR CORRELATES OF PROTECTION ANALYSES TO IDENTIFY CELLULAR AND MOLECULAR FACTORS ASSOCIATED WITH PROTECTION FROM THE ACQUISITION OF INFECTION. A MANUSCRIPT DESCRIBING THESE FINDINGS IS CURRENTLY IN PREPARATION.
IN YEAR 7, BASED ON THE DATA COLLECTED DURING THE PRECEDING YEAR, OUR RESEARCH WILL FOCUS ON EXTENDING CORRELATES OF PROTECTION STUDIES AND CONDUCTING MECHANISTIC ANALYSES TO DEFINE THE CELLULAR SUBSETS AND PATHWAYS UNDERLYING VACCINE-MEDIATED PROTECTION. WE WILL FURTHER CHARACTERIZE INFECTION KINETICS AND IMMUNE RESPONSES TO REPEATED ULTRA-LOW DOSE MTB EXPOSURE MODEL TO BETTER UNDERSTAND HOW LOW-LEVEL MTB EXPOSURE SHAPES HOST IMMUNITY AND SUBSEQUENT INFECTION OUTCOMES. TO PERFORM THESE STUDIES, WE WILL UTILIZE A BARCODED MTB STRAIN TO MONITOR INFECTION DYNAMICS UNDER REPEATED ULTRA-LOW DOSE AEROSOL CHALLENGES. FINALLY, WE WILL ALSO APPLY THIS PHYSIOLOGICALLY RELEVANT CHALLENGE MODEL TO EVALUATE THE PROTECTIVE EFFICACY OF EMERGING TB VACCINES, INCLUDING SUBUNIT MRNA, PROTEIN-BASED, AND LIVE-ATTENUATED VACCINES. SUB00002536 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: WA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $287,574 | Nov 25, 2025 | — – — |
| Subcontractor | Department of Health and Human Services | THIS STATEMENT OF WORK (SOW) OUTLINES THE ACTIVITIES THAT UNIVERSITY OF BETH ISRAEL DEACONESS MEDICAL CENTER (BIDMC) WILL BE PERFORMING. NOTE THAT THE TASK NUMBERS BELOW REFLECT THE NUMBERING OF THE OVERALL ACTIVITIES IN THE PRIME CONTRACT.
ALTHOUGH THIS SOW DETAILS THE COMPLETE SUITE OF PROPOSED WORK, THE TASKS ASSOCIATED WITH THIS CONTRACT ITERATION ARE LIMITED TO THE SPECIFIC ACTIVITIES OUTLINED BELOW, DELIVERABLES FOR THIS CONTRACT PERIOD ARE HIGHLIGHTED.
YEAR 6 €€Œ BAROUCH
OUR RESEARCH PROJECTS IN THE PRECEDING YEARS OF THE AWARD FOCUSED ON DEVELOPING INNOVATIVE MURINE AEROSOL CHALLENGE MODELS FOR THE EVALUATION OF TUBERCULOSIS VACCINES. A RECENT PUBLICATION ESTABLISHED SUBSTANTIAL VACCINE PROTECTION WITH THE LIVE-ATTENUATED ΀�LPRG VACCINE STRAIN IN THE ULTRA LOW-DOSE MURINE AEROSOL CHALLENGE MODEL AS WELL AS THE DEVELOPMENT OF A NOVEL REPEATED ULTRA LOW- DOSE CHALLENGE MODEL THAT LED TO THE IDENTIFICATION OF CORRELATES OF VACCINE PROTECTION. WE OBSERVED THAT THE NOVEL REPEATED ULTRA LOW-DOSE CHALLENGE MODEL RESULTED IN INCREASED STRINGENCY AND REDUCED VACCINE EFFICACY IN TERMS OF PROTECTION FROM DETECTABLE INFECTION AND UNILATERAL INFECTION. IN YEAR 5 WE ESTABLISHED A SECOND-GENERATION MODEL IN WHICH WE FURTHER REDUCED THE CHALLENGE INOCULUM IN ORDER TO PRESERVE A MODEL OF REPEATED EXPOSURE WHILE REDUCING THE STRINGENCY OF CHALLENGE AND IMPROVING THE LIKELIHOOD OF RESOLVING VACCINE EFFICACY.
RESEARCH EFFORTS IN YEAR 6 WILL FOCUS ON ASSESSING BCG AND ΀�LPRG VACCINE PROTECTION IN THIS SECOND-GENERATION MODEL IN THE CONTEXT OF A COMPREHENSIVE CORRELATES OF PROTECTION ANALYSIS. RESULTS FROM THE CORRELATES OF PROTECTION ANALYSES WILL BE HYPOTHESIS-GENERATING AND FORM THE BASIS FOR MECHANISTIC STUDIES EVALUATING THE CELLULAR SUBSETS AND PATHWAYS REGULATING VACCINE PROTECTION. THESE STUDIES WILL CONTINUE TO ESTABLISH NEXT-GENERATION MURINE MODELS FOR TB VACCINE TESTING, IDENTIFICATION OF CORRELATES OF PROTECTION, AND MECHANISTIC STUDIES. 13486SUB Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: WA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $363,812 | Oct 16, 2025 | — – — |
| Subcontractor | Department of Energy | BETH ISRAEL DEACONNESS MEDICAL CENTER (BIDMC) - STANDALONE - ITEM LEVEL - EMPLOYEE BENEFITS, BUSINESS INSURANCE AND ANCILLARY SERVICES (PENSION, RETIREE MEDICAL, ACTUARIAL, ETC.) CW64812 Parent award context Parent award agency: Department of Energy · Department of Energy Parent award NAICS: 561210 Parent award performance state: NM Parent award description: IGF::CL::IGF COMPETITION FOR MANAGEMENT AND OPERATION OF LOS ALAMOS NATIONAL LABORATORY View parent award on USAspending | — | $1,000,000 | Mar 10, 2025 | — – — |
| Subcontractor | Department of Defense | R&D-SCHOOLS, NON-MIT 7000637267 Parent award context Parent award agency: Department of Defense · Department of the Air Force Parent award NAICS: 541712 Parent award performance state: MA Parent award description: IGF::CT::IGF TASK ORDER 0001 FOR DOD LINE FUNDING View parent award on USAspending | FA870215D0001USAspending | $75,000 | Dec 18, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | IVY 5 - SURVEILLANCE OF ACUTELY ILL ADULTS WITH RESPIRATORY VIRUSES, INCLUDING SARS-COV-2 105573 Parent award context Parent award agency: Department of Health and Human Services · Centers for Disease Control and Prevention Parent award NAICS: 541715 Parent award performance state: TN Parent award description: SURVEILLANCE OF ACUTELY ILL ADULTS WITH RESPIRATORY VIRUSES, INCLUDING SARS-COV-2 View parent award on USAspending | — | $535,000 | Jul 22, 2024 | — – — |
| Subcontractor | Department of Energy | RAPTER-BETH ISRAEL DEACONESS MEDICAL-STANDALONE-ITEM LEVEL-DESIGN AND CONSTRUCTION SERVICES CW51395 Parent award context Parent award agency: Department of Energy · Department of Energy Parent award NAICS: 561210 Parent award performance state: NM Parent award description: IGF::CL::IGF COMPETITION FOR MANAGEMENT AND OPERATION OF LOS ALAMOS NATIONAL LABORATORY View parent award on USAspending | — | $3,000,000 | Jun 7, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | RESEARCH EFFORTS DURING YEARS 1 THROUGH 4 RESULTED IN MAJOR FINDINGS INCLUDING SIGNIFICANT VACCINE PROTECTION WITH THE ΀?LPRG STRAIN IN THE LOW-DOSE MURINE AEROSOL CHALLENGE MODEL AND DEVELOPMENT OF A NOVEL REPEATED LOW-DOSE CHALLENGE MODEL THAT LED TO THE IDENTIFICATION OF CORELATES OF VACCINE PROTECTION. WE OBSERVED THAT THE NOVEL REPEATED LOW-DOSE CHALLENGE MODEL RESULTED IN INCREASED STRINGENCY AND REDUCED VACCINE EFFICACY VIS-A-VIS PROTECTION FROM DETECTABLE INFECTION AND UNILATERAL INFECTION. RESEARCH EFFORTS IN YEAR 5 WILL FOCUS ON REFINING THE NOVEL REPEATED LOW-DOSE MURINE AEROSOL CHALLENGE MODEL. SPECIFICALLY, THE CHALLENGE INOCULUM WILL BE FURTHER REDUCED IN ORDER TO PRESERVE A MODEL OF REPEATED EXPOSURE WHILE REDUCING THE STRINGENCY OF CHALLENGE AND IMPROVING THE LIKELIHOOD OF RESOLVING VACCINE EFFICACY. THESE STUDIES WILL CONITNUE TO MAKE USE OF THE ΀?LPRG AND C3HEB/FEJ MOUSE STRAINS, RESPECTIVELY. 13206SUB Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: WA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $365,976 | Jan 31, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | SUBCONTRACT FOR IVY 5 105573 Parent award context Parent award agency: Department of Health and Human Services · Centers for Disease Control and Prevention Parent award NAICS: 541715 Parent award performance state: TN Parent award description: SURVEILLANCE OF ACUTELY ILL ADULTS WITH RESPIRATORY VIRUSES, INCLUDING SARS-COV-2 View parent award on USAspending | — | $715,000 | Sep 8, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | SUBCONTRACT FOR IVY 5 105573 Parent award context Parent award agency: Department of Health and Human Services · Centers for Disease Control and Prevention Parent award NAICS: 541715 Parent award performance state: TN Parent award description: SURVEILLANCE OF ACUTELY ILL ADULTS WITH RESPIRATORY VIRUSES, INCLUDING SARS-COV-2 View parent award on USAspending | — | $730,000 | Apr 20, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | THE BAROUCH LABORATORY AT BETH ISRAEL DEACONESS MEDICAL CENTER (BIDMC) WILL WORK CLOSELY WITH THE URDAHL LABORATORY AT SEATTLE CHILDREN€„¢S RESEARCH INSTITUTE (SCRI) IN THE EVALUATION OF TB VACCINE CANDIDATES AND THE DETERMINATION OF IMMUNE CORRELATES OF PROTECTION IN MICE. VACCINES INCLUDE BCG AND LPRG. VACCINES WILL BE EVALUATED IN MULTIPLE STRAINS OF MICE (E.G. C57BL/6, C3H/FEJ, AND C129F1) AND WILL BE ADMINISTERED BY BOTH SC AND IV ROUTES. MTB STRAINS WILL BE PROVIDED BY SCRI FOR CHALLENGE STUDIES.
IN YEAR 4, BIDMC WILL INVESTIGATE THE IMMUNOGENICITY OF THE LPRG VACCINE AND IT€„¢S PROTECTIVE EFFICACY AGAINST CHALLENGE USING SPECIFIC CONDITIONS AND COMBINATIONS OF MOUSE AND MTB CHALLENGE STRAINS BASED ON THE RESULTS OF THE SCREENING COMPLETED IN PREVIOUS YEARS. BIDMC WILL ALSO TEST ADDITIONAL VARIABLES IN THE MOST PROMISING CONDITIONS/COMBINATIONS. UNDER THESE SETTINGS BIDMC WILL INVESTIGATE IMMUNE CORRELATES OF PROTECTION IN MICE. 12926SUB Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: WA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $370,410 | Mar 31, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | EFFICACY OF HUMAN MONOCLONAL ANTIBODIES FOR POXVIRUSES AGAINST MONKEYPOX IN NONHUMAN PRIMATES 105931 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: TN Parent award description: B-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION View parent award on USAspending | — | $1,399,872 | Dec 29, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | THE RAPID PATHWAYS PATIENT PREFERENCE STUDY, AIMS TO QUANTIFY PATIENT PREFERENCES FOR BENEFIT-RISK TRADEOFFS ASSOCIATED WITH PERCUTANEOUS REVASCULARIZATION OPTIONS IN INTERMITTENT CLAUDICATION. THIS WORK WILL PROVIDE IMPORTANT DATA TO BETTER UNDERSTAND HOW PATIENTS PERCEIVE THE POSSIBLE RISK OF LATE MORTALITY ASSOCIATED WITH PACLITAXEL-COATED DEVICES. THE STUDY PHASES ARE: (1) IDENTIFYING KEY BENEFITS, RISKS AND TREATMENT FEATURES FOR A DEFINED CLINICAL SCENARIO; (2) DRAFTING, PRETESTING AND FINALIZING A SURVEY INSTRUMENT; (3) OPERATIONALIZING THE DCE SURVEY (EXPERIMENTAL DESIGN, PROGRAMMING FOR WEB-BASED SURVEY); (4) RECRUITMENT; AND (5) ANALYSIS AND REPORTING. THE PATIENT POPULATION IS EXPECTED TO REPRESENT PATIENTS WITH CURRENTLY SYMPTOMATIC OR PREVIOUSLY SYMPTOMATIC INTERMITTENT CLAUDICATION. A034237 Parent award context Parent award agency: Department of Health and Human Services · Food and Drug Administration Parent award NAICS: 541714 Parent award performance state: NC Parent award description: BAA: QUANTIFYING PATIENTS' BENEFIT-RISK TRADEOFFS ASSOCIATED WITH PERCUTANEOUS REVASCULARIZATION OPTIONS FOR PERIPHERAL ARTERIAL DISEASE: A COLLABORATIVE EFFORT WITH THE RAPID PATHWAYS PATIENT SCIENCE WORKING GROUP View parent award on USAspending | — | $47,124 | Oct 7, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | THE BAROUCH LABORATORY AT BIDMC WILL WORK CLOSELY WITH THE URDAHL LABORATORY AT SCRI IN THE EVALUATION OF TB VACCINE CANDIDATES AND THE DETERMINATION OF IMMUNE CORRELATES OF PROTECTION IN MICE. VACCINES INCLUDE BCG AND LPRG. VACCINES WILL BE EVALUATED IN MULTIPLE STRAINS OF MICE (E.G. C57BL/6, C3H/FEJ, AND C129F1) AND WILL BE ADMINISTERED BY BOTH SC AND IV ROUTES. MTB STRAINS WILL BE PROVIDED BY SCRI FOR CHALLENGE STUDIES. IN YEAR 3 WE WILL INVESTIGATE THE IMMUNOGENICITY OF THE LPRG VACCINE AND ITS PROTECTIVE EFFICACY AGAINST CHALLENGE USING SPECIFIC CONDITIONS AND COMBINATIONS OF MOUSE AND MTB CHALLENGE STRAINS BASED ON THE RESULTS OF THE SCREENING COMPLETED IN YEARS 1 & 2. WE WILL ALSO TEST ADDITIONAL VARIABLES IN THE MOST PROMISING CONDITIONS/COMBINATIONS. UNDER THESE SETTINGS WE WILL INVESTIGATE IMMUNE CORRELATES OF PROTECTION IN MICE. 12705SUB Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: WA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $370,378 | Jun 30, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | THE PURPOSE OF THIS CONTRACT IS TO EVALUATE THE EFFECTIVENESS OF VACCINES AGAINST COVID-19, INFLUENZA, AND EVENTUALLY, RSV, AMONG U.S. ADULTS WITH SEVERE ACUTE RESPIRATORY ILLNESS. THE PRIMARY AIM IS TO MONITOR EFFECTIVENESS AGAINST COVID-19-ASSOCIATED AND INFLUENZA-ASSOCIATED HOSPITALIZATIONS, INCLUDING EFFECTIVENESS AGAINST EMERGING VARIANTS OF CONCERN AND DURATION OF PROTECTION. THE CONTRACT WILL ALSO CONDUCT RSV SURVEILLANCE AMONG INPATIENTS WITH ARI AND BUILD ON PRIOR EFFORTS TO UNDERSTAND SEVERE ARI, SEVERITY SCORES, SUSCEPTIBILITY TO INFECTION, MECHANISMS OF DISEASE ATTENUATION, AND VACCINE FAILURES.
PROJECT TITLE IVY4 - SURVEILLANCE OF ACUTELY ILL ADULTS WITH RESPIRATORY VIRUSES, INCLUDING SARS-COV-2 97767 Parent award context Parent award agency: Department of Health and Human Services · Centers for Disease Control and Prevention Parent award NAICS: 622110 Parent award performance state: TN Parent award description: SURVEILLANCE OF ACUTELY ILL ADULTS WITH RESPIRATORY VIRUSES, INCLUDING SARS-COV-2 View parent award on USAspending | — | $284,000 | Jan 27, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | OPTION 18A: 0258-A705-4609
AS PREVIOUSLY DESCRIBED, WE HAVE ESTABLISHED A ROBUST CD8+ T CELL DEPLETION STRATEGY TO PROBE FOR THE ROLE OF T CELLS IN SARS€Ͽ½COV€Ͽ½2 CONTROL. IN THIS ANALYSIS, 24 ANIMALS WILL BE VACCINATED WITH THE ORIGINAL WA J&J VACCINE INSERT. IN 12 ANIMALS, CD8+ T CELLS WILL BE DEPLETED PRIOR TO B.1.351 CHALLENGE. A SIMILAR ANALYSIS WILL BE PERFORMED WITH THE P.1 VARIANT TO CONFIRM PROTECTIVE CORRELATES ARE CONSERVED ACROSS VOCS. VIRAL LOADS FOLLOWING CHALLENGE WILL DEFINE EXPLICITLY WHETHER VACCINE€Ͽ½ELICITED CD8 T CELLS ARE RESPONSIBLE FOR PROTECTION AGAINST HETEROLOGOUS CHALLENGE WITH SARS€Ͽ½COV€Ͽ½2 VARIANTS OF CONCERN.
OPTION 18D: 0258-A716-4609
WE HAVE DEVELOPED NONHUMAN PRIMATE MODELS FOR ALL THE MAJOR SARS-COV-2 VARIANTS TO DATE, INCLUDING WA1/2020, ALPHA, BETA, GAMMA, DELTA, AND MOST RECENTLY OMICRON. WE HAVE ALREADY TITRATED THE SARS-COV-2 OMICRON STOCK (FROM THE NIH SAVE CONSORTIUM) IN MACAQUES, AND THUS THE PROPOSED VACCINE STUDY CAN BE PERFORMED RAPIDLY.
WE PROPOSE TO EVALUATE THE EFFICACY OF THE CLINICAL PFIZER BNT162B2 VACCINE AND J&J AD26.COV2.S VACCINE AGAINST A HETEROLOGOUS OMICRON CHALLENGE. WE EXPECT THAT THESE VACCINES WILL LIKELY BE LESS EFFECTIVE AT PROTECTING AGAINST OMICRON INFECTION COMPARED WITH WA1/2020 INFECTION, DUE TO THE ABILITY OF OMICRON TO EVADE VACCINE-ELICITED NABS. HOWEVER, OMICRON-SPECIFIC NABS WILL LIKELY BE INDUCED FOLLOWING A BOOST IMMUNIZATION. MOREOVER, VACCINE-ELICITED T CELL RESPONSES ARE HIGHLY CROSS-REACTIVE TO OMICRON, AND THUS WE MAY OBSERVE SUBSTANTIAL CONTROL OF VIRUS REPLICATION IN THE UPPER AND LOWER RESPIRATORY TRACTS FOLLOWING INFECTION. WE WILL EVALUATE WHETHER NABS AND/OR CD8 T CELL RESPONSES ARE CORRELATES OF PROTECTION AGAINST OMICRON INFECTION AND VIROLOGIC CONTROL. WE WILL ALSO ASSESS WHETHER OMICRON INFECTION RESULTS IN MORE OF AN UPPER RESPIRATORY TRACT INFECTION AND LESS OF A LOWER RESPIRATORY TRACT INFECTION COMPARED WITH PRIOR VARIANTS.
WE WILL CHALLENGE 30 RHESUS OR CYNOMOLGUS MACAQUES WITH SARS-COV-2 OMICRON. 0258-A705-4609 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: NY Parent award description: MSSM CEIRR - THIS CONTRACT WILL SUPPORT THE NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE. View parent award on USAspending | — | $2,425,835 | Dec 14, 2021 | — – — |
| Subcontractor | Department of Health and Human Services | EVALUATE POST-INTRODUCTION EFFECTIVENESS OF VACCINATION AGAINST LABORATORY-CONFIRMED SYMPTOMATIC, MEDICALLY-ATTENDED SARS-COV-2 AND AGAINST MEDICALLY-ATTENDED INFLUENZA INFECTION WITHIN THE ESTABLISHED CDC INFLUENZA VACCINE EFFECTIVENESS IN CRITICALLY (IVY) NETWORK AND THE HOSPITALIZED ADULT INFLUENZA VACCINE EFFECTIVENESS NETWORK (HAIVEN) ? GOAL IS TO INITIATE ENROLLMENT UPON DIRECTION BY CDC SCIENCE OFFICER BASED ON SUFFICIENT VACCINATION IN TARGET GROUPS (E.G., LONG TERM CARE FACILITY RESIDENTS OR ADULTS >65 YEARS).
PROJECT TITLE IVY 3 - SARS-COV2 ADULT INPATIENT VE CASE CONTROL STUDY 89544 Parent award context Parent award agency: Department of Health and Human Services · Centers for Disease Control and Prevention Parent award NAICS: 622110 Parent award performance state: TN Parent award description: 2021 DOMAIN 1 A008 ADULT INPATIENT & OUTPATIENT VE CASE CONTROL STUDY View parent award on USAspending | HHSD200201691801IUSAspending | $657,750 | Dec 6, 2021 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.